Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Outcome
% Chance
Outcome
%Chance
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
By placing order, you agree to Terms & Conditions
Resolution Criteria
This market resolves to Yes if, on or before December 31, 2030, a drug primarily designed using artificial intelligence is granted full regulatory approval (i.e., full marketing authorization; emergency use authorizations (EUA), conditional approvals, or expanded access do not count) by one of the following regulatory agencies: FDA (US), EMA (EU centralized authorization), MHRA (UK), PMDA (Japan), or NMPA (China) for human use.
“AI-designed” means that, in official company materials and/or regulatory documentation, the drug is explicitly described as having been primarily designed or discovered using AI, where AI is credited with either:
- generating the initial lead molecular structure (or de novo scaffold) that became the approved active ingredient, or
- identifying the biological target or binding hypothesis that the approved drug acts on.
Subsequent human-led optimization and testing does not disqualify the drug.
At least one credible report or official announcement of such an approval by 2030 is required for a Yes resolution. If no such drug is approved by then, the market resolves to No.
News
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unre
DualityBio announced that China NMPA has accepted its Biologics License Application for trastuzumab pamirtecan (DB-1303/BNT323) as a second-line treatment for unresectable or metastatic HER2-positive breast cancer, based on positive interim Phase III results showing a PFS benefit over T-DM1, with collaboration plans in China and ongoing global development with BioNTech.
FDA Accepts NDA for TLX101-Px (Pixclara®)
The FDA has accepted Telix’s resubmitted NDA for TLX101-Px (Pixclara, 18F-FET) to image glioma, with a PDUFA goal date of September 11, 2026, and the program holds Fast Track and Orphan Drug designations, aiming to help distinguish tumor progression from treatment-related changes in recurrent/progressive glioma.
Telix Pharmaceuticals LimitedOnconetix Stock Up On Vinci AI Vision Launch
Onconetix stock jumped about 53% after announcing Realbotix's Vinci AI Vision System launch and the delivery of the first Vinci-equipped humanoid robot to Ericsson, with Onconetix planning an all-stock acquisition of Realbotix that is expected to close in H2 2026 and keep trading on Nasdaq.
AI-Powered Pharma Manufacturing Signals Scalable
AI-powered continuous monitoring and automation are enabling real-time, data-driven compliance in pharmaceutical manufacturing (Pharma 4.0), reducing variability, improving data integrity, and lowering long-term costs as AI, robotics, and biotech converge across the industry, with Oncotelic Therapeutics and major pharma automation players exemplifying this shift.
AINewsWireRobotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value | Business | hastingstribune.com
Regulatory tightening around contamination control, data integrity, and traceability is pushing pharmaceutical manufacturing toward automation and AI-enabled robotics, with TechForce Robotics (Nightfood Holdings) integrating autonomous, SOP-informed platforms and real-time deviation detection to reduce human involvement and address persistent aseptic and documentation gaps as AI and robotics become foundational in the industry.
AINewsWire - (GLOBE NEWSWIRE)Spinogenix’s FXS drug shows normalisation of brain function
Spinogenix’s FXS drug SPG601, a first-in-class oral tablet that modulates BKCa channels, showed normalisation of brain function by rescuing resting EEG abnormalities in a Phase IIa trial (10 adults) and is moving toward Phase IIb/III registrational trials with a favourable safety profile and designation from FDA/EMA, amid a historically underserved Fragile X market expected to grow though faces cost and heterogeneity barriers.
Abigail BeaneyInvivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and ... | Business | hastingstribune.com
Invivyd announced progress in its REVOLUTION program for VYD2311, including a planned upsize of the DECLARATION Phase 3 trial adding ~500 subjects that strengthens statistical power and may push top-line results to Q3 2026, alignment with the FDA on a pediatric plan for the pivotal trial, and the discovery and rapid development of VMS063, a novel measles monoclonal antibody candidate, with IND-enablement targeting readiness in late 2026.
Invivyd - (GLOBE NEWSWIRE)Telix FDA Accepts Pixclara NDA, Sets Sept. 11 Date | TLX Stock News
Telix announced that the FDA has accepted its resubmitted NDA for TLX101-Px (Pixclara, 18F-FET) for glioma imaging, with a PDUFA goal date of September 11, 2026, and that the asset has Orphan Drug and Fast Track designations, though Telix’ FY2026 guidance excludes TLX101-Px revenue.
Stock TitanGilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Gilead Sciences (NASDAQ:GILD), Kymera T - Benzinga
Gilead expanded its multi-year collaboration with Tempus to enhance data-driven oncology research and granted exclusive license to Kymera’s KT-200, triggering a $45 million milestone and potentially up to $750 million in total payments for Kymera as Gilead advances KT-200 toward an IND filing in 2027, alongside broader access to Tempus’ AI Lens platform for oncology initiatives.
Vandana SinghMassive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients - Las Vegas Sun News
Massive Bio reports a prospective real-world study (3,804 metastatic cancer patients in 2024) showing its neuro-symbolic, multi-agent AI platform matches patients to clinical trials four times faster (about 30 minutes vs 120) with an F1 of 0.82 (0.84 sensitivity and specificity), over 17,000 oncologist-validated matches, while preserving equity, using a three-agent architecture and an oncology knowledge graph with human oversight.